|
|||||||||||
 |
|||||||||||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
PROACTIVE PUBLISHED PAPERS
A number of pivotal PROactive papers and letters have now been published. These are listed below and a number of them are also available to download.
Publications
Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care 2004;27:1647–1653
Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 2005;366:1279–1289
To download a copy of this publication please click here and follow the instructions carefully
Bottomley J, Palmer A, Williams R, Massi-Benedetti M, Dormandy J. PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events —economic implications (REVIEW). Br J Diabetes Vasc Dis 2006;6:63–70
Wilcox R, Bousser M-G, Pirag V, Betteridge J, Schernthaner G, Kupfer S, Dormandy J. PROactive 04: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke — results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events. Stroke 2007; 38:865–873
To download a copy of this publication please click here and follow the instructions carefully
Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; on behalf of the PROactive investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction—Results from PROactive (PROactive 05). JACC 2007; 49:1772–1780 To download a copy of this publication please click here and save to your computer
Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M on behalf of the PROactive Study Group. PROactive 06: Cost effectiveness of pioglitazone in type 2 diabetes in the UK. Diabetic Med 2007;4:982–1002
Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. PROactive 07: Pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Clin Risk Management 2007; 3:355–370
Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan MH, Spanheimer R, Standl E, Dormandy JA on behalf of the PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30:2773–2778
Schneider CA, Ferrannini E, DeFronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in patients with diabetes and chronic kidney disease. J Am Soc Nephr 2008;19:182–187
Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROactive (PROactive 10). Am Heart J 2008; 155:712–717
Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L, on behalf of the PROactive investigators. Impact of peripheral arterial disease in patients with diabetes — results from PROactive (PROactive 11). Atherosclerosis 2009; 202:272–281.
Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: A US analysis based on PROactive. Value Health 2009;121–129.
Dormandy J, Van Troostenburg de Bruyn A, Bhattacharya M. Overall safety of pioglitazone in high-risk patients with type 2 diabetes. Drug Saf 2009;32:187–202.
Spanheimer R, Charbonnel B, Betteridge DJ, Tan TH. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol 2009;104234–104239.
Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff Resour Alloc 2009 May 5;7:9.
Brändle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med Wkly 2009;139:173–184.
Scheen A, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B on behalf of the PROactive investigators. Long-term glycaemic control with metformin-sulfonylurea-pioglitazone triple therapy in the PROactive study (PROactive 17). Diabet Med 2009; in press
Letters
The PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study [letter]. Lancet 2006;367:982
The PROactive Study Executive Committee and Data and Safety Monitoring Committee. Competing Perspectives on PROactive [letter]. Clin Diabetes 2006;25:3
Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive [letter]. Lancet 2007;368:189–190
To download a copy of this publication please click here and follow the instructions carefully